Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia

Current Opinion in Lipidology

Volumn 21, Issue 4, 2010, Pages 366-371

  Datta, Borunendra N ^a   McDowell, Ian F W ^a,b   Rees, Alan ^a,b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LIPID;

DIAGNOSTIC PROCEDURE; DNA SCREENING; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HEALTH SERVICE; MEDICAL SPECIALIST; PRIORITY JOURNAL; REVIEW; HUMAN; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; MASS SCREENING; MEDICINE; METABOLISM; PROCEDURES;

HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; LIPIDS; MASS SCREENING; MEDICINE;

EID: 77954956771     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833c14e2     Document Type: Review

References (22)

1. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49:476-488.
2. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hy-percholesterolaemia: a prospective registry study. Eur Heart J 2008; 29:2625-2633.
3. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337:a2423.
4. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357:165-168.
5. Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholes-terolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 2008; 11:26-35.
6. Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med 2004; 4:67-74
7. The Cardiac Society of Australia and New Zealand Guidelines for the diagnosis and management of Familial Hypercholesterolaemia. http://www.csanz. edu.au/Portals/0/Guidelines/Practice/Guidelines%20for%20Clinical% 20Practice%20-%20Familial%20Hypercholesterolaemia.pdf.
8. National Institute for Health and Clinical Excellence Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. (Clinical guideline 71); 2008.
9. Tosi I, Toledo-Leiva P, Neuwirth C, et al. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis 2007; 194:102-111.
10. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43:943-949.
11. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37:161-165.
12. McDowell I, Watson M, Townsend D, et al. An evaluation of DNA diagnostics for familial hypercholesterolaemia including a study of personal and family implications [abstract]. Atherosclerosis 2007; 194:282.
13. Bhatnagar D, Morgan J, Siddiq S, et al. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000; 321:1497-1500.
14. Marks D, Thorogood M, Neil SM, et al. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen 2006; 13:156-159.
15. Marks D, Wonderling D, Thorogood M, et al. Screening for hypercholester-olaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000; 4:1-123.
16. Defesche JC, Lansberg PJ, Umans-Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med 2004; 4:59-65.
17. Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, et al. Cost-effectiveness of a family and DNA based screening programme on familial hyper-cholesterolaemia in The Netherlands. Eur Heart J 2002; 23:1922-1930.
18. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 2004; 4:97-104.
19. FH GIT Toolkit. http://www.heartuk.org.uk/FHToolkit/.
20. Young KV HS, Grant R. National Clinical Audit of the management of familial hypercholesterolaemia 2009: pilot-full report. In: Clinical Effectiveness and Evaluation Unit RCoP; June 2009.
21. A certification program for clinical lipid specialists. www.lipidboard.org. [Accessed 2010]
22. Hadfield SG, Horara S, Starr BJ, et al. Are patients with familial hyper-cholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project. Ann Clin Biochem 2008; 45:199-205.